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Abstract
Background: Microglial activation has been proposed to facilitate clearance of amyloid β protein
(Aβ) from the brain following Aβ immunotherapy in amyloid precursor protein (APP) transgenic
mice. Interleukin-1 receptor 1 knockout (IL-1 R1-/-) mice are reported to exhibit blunted
inflammatory responses to injury. To further define the role of IL-1-mediated inflammatory
responses and microglial activation in this paradigm, we examined the efficacy of passive Aβ
immunotherapy in Tg2576 mice crossed into the IL-1 R1-/- background. In addition, we examined
if loss of IL-1 R1-/- modifies Aβ deposition in the absence of additional manipulations.
Methods: We passively immunized Tg2576 mice crossed into the IL-1 R1-/- background (APP/IL-
1 R1-/- mice) with an anti-Aβ1-16 mAb (mAb9, IgG2a) that we previously showed could attenuate
Aβ deposition in Tg2576 mice. We also examined whether the IL-1 R1 knockout background
modifies Aβ deposition in untreated mice. Biochemical and immunohistochemical Aβ loads and
microglial activation was assessed.
Results: Passive immunization with anti-Aβ mAb was effective in reducing plaque load in APP/IL-
1 R1-/- mice when the immunization was started prior to significant plaque deposition. Similar to
previous studies, immunization was not effective in older APP/IL-1 R1-/- mice or IL-1 R1 sufficient
wild type Tg2576 mice. Our analysis of Aβ deposition in the untreated APP/IL-1 R1-/- mice did not
show differences on biochemical Aβ loads during normal aging of these mice compared to IL-1 R1
sufficient wild type Tg2576 mice.
Conclusion: We find no evidence that the lack of the IL-1 R1 receptor influences either Aβ
deposition or the efficacy of passive immunotherapy. Such results are consistent with other studies
in Tg2576 mice that suggest microglial activation may not be required for efficacy in passive
immunization approaches.
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Background
Direct immunization with aggregated amyloid β protein
(Aβ) and passive immunization with anti-Aβ antibodies
(Abs) reduce plaque burden in Alzheimer's disease (AD)
mouse models and improve cognitive deficits present in
those models [1-5]. Although no adverse effects of immu-
nization were noted in earlier studies, more recent data in
mice indicate that there is the potential of exacerbation of
cerebral-amyloid angiopathy (CAA) associated microhe-
mmorhages in certain mouse strains following passive
immunization with certain anti-Aβ antibodies [6-8]. An
active immunization trial in humans was initiated using
fibrillar Aβ42+QS-21 adjuvant (AN-1792) but was halted
due to a meningio-encephalitic presentation in ~6% of
individuals [9-11]. Reports of individuals enrolled in the
trial suggest that those subjects who developed modest
anti-plaque antibody (Ab) titers did show some clinical
benefit relative to subjects that did not develop detectable
titers [9,11,12]. A small phase II study of AD patients
administered human IVIG containing anti-Aβ Abs
showed slight improvement in ADAScog following
administration; however the clinical effect was modest
and only a few subjects were evaluated [13].
Given the pre-clinical data, hints of efficacy in humans,
and the lack of disease-modifying therapies for AD, Aβ
immunotherapy or derivative approaches are still worthy
of pursuing. However, the mechanism or mechanisms
through which Aβ immunotherapy works remain enig-
matic [14,15]. The amount of Aβ deposited when immu-
nization is initiated, the AD mouse model used, and the
properties of the anti-Aβ antibodies used, all affect the
outcome [1,2,16-18]. One of the debates with respect to
mechanism centers on peripheral versus a central action
of the antibody [3,19,20]. There is evidence to support
both mechanisms, and it will be a very difficult issue to
definitively address this through additional experimenta-
tion. Another debate is in regard to the role of microglia
activation. Several groups report transient or stable
enhancements of microglia activation associated with Aβ
removal; others do not [1,21-23]. In postmortem human
tissue from AD patients who had received the AN-1792
vaccine, Aβ-laden microglia were noted in areas where Aβ
clearance is hypothesized to have occurred [24]. Thus,
microglial activation has been proposed to facilitate
removal of Aβ from the brain following vaccination.
The IL-1 superfamily (including IL-1β, IL-1α and IL-18) is
a group of cytokines that exhibit a large number of biolog-
ical responses [25]. Interleukin-1β is a key mediator of
host response to infections and a primary cause of inflam-
mation [25]. In vivo, IL-1β is elevated during infections
and in several chronic inflammatory diseases such as
arthritis, scleroderma, systemic lupus erythematosus, vas-
culitis, sepsis, septic shock, and atherosclerotic lesions as
well as in brains of AD patients [25]. As least two IL-1
receptors (IL-1R) have been identified: type I and type II
receptors (IL-RI and IL-RII) [26]. IL-1β binds IL-1RI and
upon IL-1 binding, IL-1RI recruits the accessory protein
IL-1R-AcP, and initiates a stimulatory signal transduction
cascade [26]. IL-1RII acts as a decoy receptor and com-
petes with IL-1RI to down-modulate IL-1 activity [27]. In
AD and Down's syndrome, IL-1β production is increased
in microglial cells in the vicinity of amyloid plaques
[28,29]. Initial studies examining the association of poly-
morphisms in the IL-1 and IL-1 receptor genes showed
positive association of certain alleles with AD risk [30-34].
However, like many AD genetic association studies, sub-
sequent studies failed to confirm the initial association.
Meta-analyses of all studies on IL-1α and β linkage show
no evidence for association of these loci with AD http://
www.alzforum.org/res/com/gen/alzgene/. A recent report
shows that activation of microglia with secreted APP
(sAPPα) results in a dose-dependent increase in secreted
IL-1β [35]. Similarly, cortical neurons treated with IL-1β
showed a dose-dependent increase in sAPPα secretion,
elevated levels of α-synuclein and phosphorylated tau
[35]. In APP transgenic mice, IL-1 reactivity and other
inflammatory markers are increased in microglial cells
surrounding amyloid deposits during various stages of
amyloid deposition in these mice [36,37]. Another mem-
ber of the IL-1 superfamily, IL-1 receptor antagonist (IL-
1Ra) [38], is also synthesized and released in parallel to
IL-1β, IL-1α, and IL-18. IL-1Ra binds to IL-1RI and blocks
IL-1 dependent signal transduction, thus functioning as
an endogenous, IL-1 selective inhibitor of inflammation
[38]. Interestingly, IL-1Ra knockout mice show enhanced
microglial activation and neuronal damage following
intracerebroventricular infusion of human Aβ [39]. Col-
lectively, these data suggest that IL-1 is a key mediator of
microgliosis and subsequent inflammatory responses fol-
lowing Aβ deposition as well as in the production of sub-
strates necessary for neuropathological changes seen in
AD.
To gain additional insight into the role of IL-1 signaling
on microglial activation, on IL-1-mediated inflammatory
responses following Aβ vaccination, and on Aβ deposi-
tion during normal aging, we used interleukin-1 receptor
1-knockout (IL-1 R1-/-) mice [40-42] that were crossed to
APP Tg2576 transgenic mice (APP/IL-1 R1-/-). The IL-1
R1-/- mice lack the type 1 interleukin-1 receptor, but
develop normally. Moreover, with a few exceptions, these
mice are normal, showing alterations in IL-1-mediated
immune response to certain stimuli. Following penetrat-
ing brain injury in IL1-R1-/- mice, fewer amoeboid micro-
glia/macrophages are present near the sites of injury,
astrogliosis is mildly abrogated and cyclooxygenase-2
(Cox-2) and IL-6 expression are reduced [42]. In another
report, IL-1 R1-/- mice failed to respond to IL-1 in severalJournal of Neuroinflammation 2006, 3:17 http://www.jneuroinflammation.com/content/3/1/17
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assays, including IL-1-induced IL-6 and E-selectin expres-
sion, and IL-1-induced fever and acute-phase responses to
turpentine [41]. These data in IL-1 R1-/- mice demonstrate
that IL-1 R1 is critical for most IL-1-mediated signaling
events tested. We performed passive immunization with
an anti-Aβ mAb in Tg2576 mice crossed into the IL-1 R1-
/- background (APP/IL-1 R1-/-), and determined whether
microglial activation and consequent inflammatory
responses are necessary for Aβ reduction. These studies
show that passive immunization with anti-Aβ mAb is
effective in reducing plaque load in APP/IL-1 R1-/- mice
when the immunization is started prior to significant
plaque deposition and thus support our general hypothe-
sis that microglial activation may not be required for effi-
cacy of immunization in Tg2576 mice.
Methods
Mice breeding strategy
Tg2576 [43] were bred into the IL-1 R1-knockout back-
ground (B6.129S7-Il1r1tm1Imx, Jackson Laboratories) as
follows; male Tg2576 (C57BL/6.SJL) were initially
crossed with IL-1 R1-/- females (B6.129S7). We then back-
crossed the F1 Tg2576 × IL-1R1+/- males with female IL-1
R1-/-. These crosses generated the F2 Tg2576 × IL-1R1-/-
mice (APP/IL-1 R1-/-) and Tg2576 × IL-1R1+/- littermates
(APP/IL-1 R1+/-), which were used in all experiments. All
animal experimental procedures were performed accord-
ing to Mayo Clinic Institutional Animal Care and Use
Committee guidelines. All animals were housed three to
five to a cage and maintained on ad libitum and water with
a 12 h light/dark cycle.
Passive immunizations
Groups of APP/IL-1 R1-/- mice and APP/IL-1 R1+/- litter-
mates (males and females, 6-month-old or 12-month-
old, n = 3-5/group) were immunized intraperitoneally
(i.p.) with 500 μg of mAb9 (Aβ1-16 specific, IgG2a) in
saline once every 2 weeks for 3 months. Control mice
received 500 μg of purified mouse IgG in saline.
ELISA analysis of extracted Aβ
At sacrifice, the brains of mice were divided by midsagittal
dissection, and 1 hemibrain was used for biochemical
analysis as described previously [18]. Briefly, each hemi-
brain (150 mg/ml wet wt) was extracted in 2% SDS with
protease inhibitors using a polytron and centrifuged at
100,000 g for 1 hour at 4°C. Following centrifugation, the
supernatant was collected, which represented the SDS-sol-
uble fraction. The resultant pellet was then extracted in
70% FA, using a probe sonicator, centrifuged at 100,000 g
for 1 hour at 4°C, and the supernatant collected (the FA
fraction). Extracted Aβ was then measured using a sand-
wich ELISA system as described before [18]; Aβ 42-capture
with mAb 2.1.3 (mAb40.2,) and detection with HRP-con-
jugated mAb Ab9 (human Aβ1-16 specific); Aβ40- capture
with mAb Ab9 and detection with HRP-conjugated mAb
13.1.1 (mAβ40.1)
Immunohistology
Hemibrains of mice were fixed in 4% paraformaldehyde
in 0.1 M PBS (pH 7.6) and then stained for Aβ plaques as
described previously [18]. Paraffin sections (5 μm) were
pretreated with 80% FA for 5 minutes, boiled in water
using a rice steam cooker, washed, and immersed in 0.3%
H2O2 for 30 minutes to block intrinsic peroxidase activ-
ity. They were then incubated with 2% normal goat serum
in PBS for 1 hour, with 33.1.1 (Aβ1-16 mAb) at 1 μg/ml
dilution overnight, and then with HRP-conjugated goat
anti-mouse secondary mAb (1:500 dilution; Amersham
Biosciences) for 1 hour. Sections were washed in PBS, and
immunoreactivity was visualized by 3,3'-diaminobenzi-
dine tetrahydrochloride (DAB) according to the manufac-
turer's specifications (ABC system; Vector Laboratories).
Adjacent sections were stained with 4% thioflavin-S for 10
minutes. Free-floating 4% paraformaldehyde-fixed, fro-
zen tissue sections (30 μM) were stained for the presence
of activated microglia with rat anti-mouse CD45 (1:3000;
Serotec, Oxford, UK), followed by detection with anti-rat-
HRP (ABC system, Vector Labs), and then counterstained
with Thio-S as described previously [23]. Four percent
paraformaldehyde-fixed, paraffin-embedded sections
were stained for activated microglia using anti-Iba1
(1:3000; Wako Chemicals) and for activated astrocytes
using anti-GFAP (1:1000, Chemicon).
Quantitation of amyloid plaque burden
Computer-assisted quantification of Aβ plaques was per-
formed using he MetaMorph 6.1 software (Universal
Imaging Corp, Downington, PA). Serial coronal sections
stained as above were captured, and the threshold for
plaque staining was determined and kept constant
throughout the analysis. For analysis of plaque burdens in
the passive immunization experiments, immunostained
plaques were quantified (proportional area of plaque bur-
den) in the neocortex of the same plane of section for each
mouse (~10 sections per mouse). All of the above analyses
were performed in a blinded fashion.
Statistical analysis
One-way ANOVA followed by Dunnett's multiple com-
parison tests were performed using the scientific statistic
software Prism (version 4; GraphPad).
Results
Interleukin-1 receptor 1 knockout has no effect on Aβ 
loads in Tg2576 mice
To investigate whether the lack of IL-1 R1 had any effect
on Aβ deposition, we analyzed biochemically extractable
Aβ levels and immuno-reactive plaque burdens in Tg2576
mice crossed to IL-1 R1-/- mice (APP/IL-1 R1-/-). APP/IL-Journal of Neuroinflammation 2006, 3:17 http://www.jneuroinflammation.com/content/3/1/17
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1 R1-/- mice were compared to APP/IL-1 R1+/-
hemizygous littermates to control for differences in the
background genes, as a result of our breeding strategy
(Tg2576 in F1 C57BL/6.SJL background and IL1-R1-/-
mice in B6.129S7 background). Thus, APP/IL-1 R1-/- mice
and APP/IL-1 R1+/- hemizygous littermates generated are
in similar mixed C57BL/6.SJL and C57BL/6.129S7 back-
grounds. We have also compared the crossed mice to wild
type Tg2576 mice (referred to as IL-1 R1+/+) in various
measurements, though these mice are in a different back-
ground (F2 C57BL/6.SJL).
Groups of mice at various ages (6 months, 9 months and
15 months of age) were killed and the levels of both SDS-
soluble (SDS) and SDS-insoluble FA-extractable fractions
of Aβ40 and Aβ42 were analyzed by ELISA. As shown in
Figure 1, there were no significant differences in the
amounts of extractable Aβ in all three ages groups tested
when we compared Aβ levels in APP/IL-1 R1-/-, APP/IL-1
R1+/- littermates and wild type Tg2576 mice: SDS Aβ42
(Figure 1A), SDS Aβ40 (Figure 1B), FA Aβ42 (Figure 1C),
and FA Aβ40 (Figure 1D). To further examine whether
there were alterations in deposited Aβ plaques in these
Aβ levels in APP/IL-1 R1-/- mice, APP/IL-1 R1+/-littermates and wild type Tg2576 mice at 6 months, 9 months and 15 months  of age Figure 1
Aβ levels in APP/IL-1 R1-/- mice, APP/IL-1 R1+/-littermates and wild type Tg2576 mice at 6 months, 9 months and 15 months 
of age. Groups of mice were killed at the indicated time points and both SDS-soluble (SDS) and SDS-insoluble, formic acid 
extractable (FA) fractions of Aβ40 and Aβ42 were measured by capture ELISA.
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mice, coronal sections of each mouse hemibrain were
analyzed for changes in immunostained Aβ plaque loads.
Quantitative image analysis of amyloid plaque burden in
all age groups revealed no significant differences (data not
shown). However, in 2 of 7 mice analyzed in the 15-
month-old APP/IL-1 R1-/-, there was atypical Aβ plaque
staining. An appreciable increase in diffuse immuno-reac-
tive Aβ plaques (Figure 2B) in the neocortex of these 2
mice was noted when compared to the 15-month-old
APP/IL-1 R1+/- littermates (Figure 2A) or wild type
Tg2576 mice (Figure 2C), which deposit more dense-
cored Aβ plaques at this age.
Passive immunotherapy is effective in young APP/IL-1 R1-/
- mice
To examine the effects of microglial activation on Aβ
immunotherapy, we examined the effects of passive
immunization with an anti-Aβ monoclonal antibody
(mAb9) in APP/IL-1 R1-/-mice. Two experimental para-
digms were used: i) a prevention study, in which passive
immunization was performed in 6-month-old mice,
which at this time have minimal Aβ deposition, and ii) a
therapeutic study, in which immunotherapy was per-
formed using 12-month-old mice, which have moderate
levels of preexisting Aβ deposits. Both groups of mice were
treated for 3 months then killed; and biochemical and
immunohistochemical methods were used to analyze the
effect of immunotherapy. Following passive immuniza-
tion with mAb9 initiated in the 6-month-old mice (pre-
vention study), Aβ levels were significantly attenuated in
both the APP/IL-1 R1-/- and APP/IL-1 R1+/- littermates
(Figure 3). Both the SDS-extractable Aβ levels (>50%
reduction in SDS Aβ; Figure 3A and 3B) and formic acid-
(FA-) solubilized, SDS-insoluble material (>50% reduc-
tion in FA Aβ; Figure 3A and 3B) were reduced in these
mice. Quantitative image analysis of immunostained sec-
tions also showed a significant decrease in Aβ deposition
in both groups (as measured by plaque numbers per field,
Figure 3E). In contrast, passive immunization with mAb9,
initiated in the 12-month-old mice (therapeutic study)
had no significant effect on biochemically extracted Aβ
levels (Figure 3C and 3D) or immuno-reactive Aβ; plaque
loads (Figure 3F), in the both the APP/IL-1 R1-/- or APP/
IL-1 R1+/- littermates.
Interleukin-1 receptor 1 knockout has no effect on 
microglial reactivity surrounding Aβ plaques
To access whether the IL-1 R1-/- phenotype affected the
state of microglial activation, and astrocyte reactivity, par-
ticularly, glial reactivity surrounding amyloid plaques, we
compared the intensity of staining of microglia using anti-
bodies against CD45, a marker for activated microglia that
has been shown to be present on activated microglia sur-
rounding amyloid plaques in APP transgenic mice [44]
and Iba1, the ionized calcium-binding adaptor molecule
1, which is expressed selectively in activated microglia/
macrophages [45]. For CD45 staining, coronal sections
from both unmanipulated APP/IL-1 R1-/-, APP/IL-1 R1+/
Representative pictures of immunostained Aβ plaques  (stained with anti-Aβ antibody) in the neocortex of (A) a 15- month-old APP/IL-1 R1+/- mouse; (B) a 15-month-old APP/ IL-1 R1-/- mouse; and (C) a 15-month-old wild type Tg2576  mice (IL_1 R1+/+) Figure 2
Representative pictures of immunostained Aβ plaques 
(stained with anti-Aβ antibody) in the neocortex of (A) a 15-
month-old APP/IL-1 R1+/- mouse; (B) a 15-month-old APP/
IL-1 R1-/- mouse; and (C) a 15-month-old wild type Tg2576 
mice (IL_1 R1+/+). (A, B, C, magnification = 100×, insert 
shows enlargement of Aβ plaques).Journal of Neuroinflammation 2006, 3:17 http://www.jneuroinflammation.com/content/3/1/17
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A and B. Aβ levels were significantly reduced following mAb9 immunizations initiated in 6-month-old APP/IL-1 R1-/- mice as  well as APP/IL-1 R1+/- mice (n = 3/group) Figure 3
A and B. Aβ levels were significantly reduced following mAb9 immunizations initiated in 6-month-old APP/IL-1 R1-/- mice as 
well as APP/IL-1 R1+/- mice (n = 3/group). C and D. Aβ levels were not significantly altered following mAb9 immunizations 
initiated in 12-month-old APP/IL-1 R1-/- mice and APP/IL-1 R1+/- mice (n = 3–5/group). Mice were killed after immunization 
with 500 μg of mAb9 every other week for 3 months, and both SDS-soluble (SDS) and SDS-insoluble, formic acid extractable 
(FA) fractions of Aβ40 and Aβ42 were measured by capture ELISA. E and F. Quantitative image analysis of amyloid plaque 
burden in the neocortex of mAb9 immunizations initiated in 6-month-old APP/IL-1 R1-/- mice (E) and mAb9 immunizations 
initiated in 12-month-old APP/IL-1 R1-/- mice (F). (*, ** P < 0.05 t-test)
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- littermates and wild type Tg2576 mice (IL-1 R1 +/+) at 9-
months and 15-months of age were used for staining. As
shown in Figure 4, there were abundant numbers of CD45
immuno-reactive microglia present, surrounding Aβ
plaques from the 9-month-old APP/IL-1 R1-/- (Figure
4A), APP/IL-1 R1+/- littermates (Figure 4C) and wild type
Tg2576 mice (Figure 4E) with no obvious differences in
the CD45 reactivity in these activated microglial cells.
Greater numbers of immuno-reactive microglia were
present surrounding plaques in the 15-month-old mice,
but again, there were no discernable differences in the
density/CD45 reactivity in these microglial when we com-
pared sections from the 15-month-old APP/IL-1 R1-/-
(Figure 4B) vs. 15-month-old APP/IL-1 R1+/- littermates
(Figure 4D) or wild type Tg2576 mice (Figure 4F). Similar
results were seen when we compared the CD45 reactivity
of microglia in mice that were passively immunized with
mAb9 vs. controls, i.e., there were no differences in micro-
glial reactivity using CD45 staining comparing immu-
nized mice vs. controls in both groups (data not shown).
For anti-Iba1 antibody staining, we compared coronal sec-
tions from unmanipulated APP/IL-1 R1-/-, APP/IL-1 R1+/
- littermates and wild type Tg2576 mice (IL-1R1+/+) at 9
months and 15 months of age. As shown in Figure 5, anti-
Iba1 staining was readily detected in microglia surround-
ing Aβ plaques in all three groups of mice tested compar-
ing both 9-month-old and 15-month-old mice (Figure 5).
Similar to CD45 staining, there were no discernable differ-
ences in the Iba1 reactivity in microglial cells comparing
the APP/IL-1 R1-/-, APP/IL-1 R1+/- littermates and wild
type Tg2576 mice (IL-1R1+/+) mice. For staining of acti-
vated astrocytes, we used an anti-GFAP antibody and
compared immunoreactivity using coronal sections from
unmanipulated APP/IL-1 R1-/-, APP/IL-1 R1+/- litterma-
tes and wild type Tg2576 mice (IL-1R1+/+) at 9 months
and 15 months of age as before. As shown in Figure 6,
there was robust anti-GFAP reactivity on activated astro-
cytes surrounding Aβ plaques in all three groups of mice
tested (Figure 6). Again, similar to the microglial staining
pattern, there were no discernable differences in the GFAP
reactivity on astrocytes in all three groups of mice tested.
Discussion
Despite multiple studies of anti-Aβ immunotherapy in
mice, there is still no consensus on how anti-Aβ immuno-
therapy works [14,15], particularly as it relates to the role
of microglial activation. It was originally proposed that Aβ
immunization triggers phagocytosis of antibody-bound
Aβ immune complexes via microglial FcR. After immuni-
zation, increased number of microglial cells stained with
anti-Aβ antibodies were observed [1]. Indeed, using an ex
vivo strategy, it was shown that anti-Aβ antibodies induce
phagocytosis of Aβ plaques [2]. Importantly, Fab frag-
ments of these antibodies fail to induce Aβ phagocytosis,
suggesting that the enhanced uptake is attributable to FcR
[2]. Subsequent studies have shown that at least in
Tg2576 APP mice, a role for enhanced phagocytosis of
mAb:Aβ complexes via the FcR can largely be ruled out,
since Aβ1-42 immunization in Tg2576 × FcRγ-/- crossed
mice was effective in reducing Aβ loads [23]. Additional
studies now show that an intact mAb (and therefore FCR
interactions) is not required for efficacy; since Fab frag-
ments [46] and scFv fragments (Levites and Golde,
unpublished observation) are efficacious in immuno-
therapy. Several groups have reported that following Aβ
immunotherapy, there are transient or stable enhance-
ments of microglial activation associated with Aβ
removal; whereas others do not find this [1,21-23]. Fur-
thermore, in humans receiving the AN-1792 vaccine, Aβ-
laden microglia have been noted in postmortem studies
[24]. Although antibody and microglial Fc receptor-medi-
ated interactions have been suggested to activate micro-
glia following vaccinations, other inflammatory
consequences may play a role in this paradigm. Based on
published reports, it has been suggested that clearance of
amyloid deposits in patients enrolled in the AN-1792 trial
may have been due to an adverse inflammatory response
to the vaccine rather than due to the anti-Aβ antibodies
[47]. This proposition may be supported by some recent
reports, wherein induction of experimental autoimmune
encephalitis (EAE) and nasal vaccination with glatiramer
acetate reportedly decrease amyloid plaques in APP trans-
genic mice [48]. Another report by the same group shows
that, in mice over expressing IFN-gamma in the CNS,
amyloid vaccination lead to meningoencephalitis and T
cell-dependent clearance of amyloid plaques from the
brain [49]. Both of these reports provide evidence that
peripheral inflammatory responses and CNS autoreactive
T cells may play a role in vaccination-induced clearance of
plaques. Furthermore, some recent reports have indicated
that inflammatory insults, either by injecting LPS directly
into the brain [44,50] or overexpression of TGF-β in the
CNS [51], can result in reductions of amyloid deposits.
Enhanced microglial activation was noted in both of these
reports and is suggested to contribute to the clearance of
amyloid deposits.
In this report, we sought to determine the role of IL-1-
mediated microglial activation on IL-1-mediated inflam-
matory responses following Aβ vaccination and on Aβ
deposition during normal aging using interleukin-1
receptor 1-knockout (IL-1 R1-/-) mice [40-42] that were
crossed to APP Tg2576 transgenic mice (APP/IL-1 R1-/-).
We first tested the efficacy of Aβ immunization in APP/IL-
1 R1-/- mice. Our results show that passive immunization
with an anti-Aβ mAb is effective in reducing plaque loads
both in APP/IL-1 R1-/- mice and APP/IL-1 R1+/- litterma-
tes, when immunization is started prior to significant
plaque deposition. However, as we have seen previously,
immunization was not efficacious in mice that have pre-Journal of Neuroinflammation 2006, 3:17 http://www.jneuroinflammation.com/content/3/1/17
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Representative pictures of Thioflavin-S-stained Aβ plaques (lightly stained areas) decorated with ramified microglia immunos- tained with anti-mouse CD45 (black stain) in the neo cortex of untreated (A) 9-month-old APP/IL-1 R1-/- and (B) 15-month- old APP/IL-1 R1-/-; (C) 9-month-old APP/IL-1 R1+/- and (D) 15-month-old APP/IL-1 R1+/-; (E) 9-month-old wild type Tg2576  mice (IL-1 R1+/+) and (F) 15-month-old wild type Tg2576 mice (IL-1 R1+/+) Figure 4
Representative pictures of Thioflavin-S-stained Aβ plaques (lightly stained areas) decorated with ramified microglia immunos-
tained with anti-mouse CD45 (black stain) in the neo cortex of untreated (A) 9-month-old APP/IL-1 R1-/- and (B) 15-month-
old APP/IL-1 R1-/-; (C) 9-month-old APP/IL-1 R1+/- and (D) 15-month-old APP/IL-1 R1+/-; (E) 9-month-old wild type Tg2576 
mice (IL-1 R1+/+) and (F) 15-month-old wild type Tg2576 mice (IL-1 R1+/+). (A, B, C, D, E, F magnification = 400×).Journal of Neuroinflammation 2006, 3:17 http://www.jneuroinflammation.com/content/3/1/17
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existing Aβ loads [17,18,52]. Thus, these results support
our general hypothesis that microglial activation may not
be required for efficacy of immunization in Tg2576 mice.
The lack of IL-1 R1 (in -/- mice) did not significantly alter
Aβ deposition in untreated mice. There were no signifi-
cant differences in total extractable Aβ levels or overall his-
tochemical loads, at any time, between the APP/IL-1 R1-/
- mice and APP/IL-1 R1+/- littermates compared to wild
Representative pictures of Thioflavin-S-stained Aβ plaques (lightly stained areas) decorated with microglia immunostained with  anti-Iba1 (brown stain) in the neocortex of untreated (A) 9-month-old APP/IL-1 R1-/- and (B) 15-month-old APP/IL-1 R1-/-;  (C) 9-month-old APP/IL-1 R1+/- and (D) 15-month-old APP/IL-1 R1+/-; (E) 9-month-old wild type Tg2576 mice (IL-1 R1+/+)  and (F) 15-month-old wild type Tg2576 mice (IL-1 R1+/+) Figure 5
Representative pictures of Thioflavin-S-stained Aβ plaques (lightly stained areas) decorated with microglia immunostained with 
anti-Iba1 (brown stain) in the neocortex of untreated (A) 9-month-old APP/IL-1 R1-/- and (B) 15-month-old APP/IL-1 R1-/-; 
(C) 9-month-old APP/IL-1 R1+/- and (D) 15-month-old APP/IL-1 R1+/-; (E) 9-month-old wild type Tg2576 mice (IL-1 R1+/+) 
and (F) 15-month-old wild type Tg2576 mice (IL-1 R1+/+). (A, B, C, D, E, F magnification = 400×).Journal of Neuroinflammation 2006, 3:17 http://www.jneuroinflammation.com/content/3/1/17
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type Tg2576 mice (IL-1 R1+/+). Curiously, in 2 of 7 15-
month-old APP/IL-1 R1-/- mice examined, an unusual
pattern of Aβ plaque staining was noted, with an abun-
dance of diffuse immuno-reactive Aβ plaques in the neo-
cortex of these mice. It is not clear at this time whether this
unusual pattern of diffuse Aβ deposits is due to the IL-1
Representative pictures of Thioflavin-S-stained Aβ plaques (lightly stained areas) decorated with activated astrocytes immunos- tained with anti-GFAP (brown stain) in the neocortex of untreated (A) 9-month-old APP/IL-1 R1-/- and (B) 15-month-old  APP/IL-1 R1-/-; (C) 9-month-old APP/IL-1 R1+/- and (D) 15-month-old APP/IL-1 R1+/-; (E) 9-month-old wild type Tg2576  mice (IL-1 R1+/+) and (F) 15-month-old wild type Tg2576 mice (IL-1 R1+/+) Figure 6
Representative pictures of Thioflavin-S-stained Aβ plaques (lightly stained areas) decorated with activated astrocytes immunos-
tained with anti-GFAP (brown stain) in the neocortex of untreated (A) 9-month-old APP/IL-1 R1-/- and (B) 15-month-old 
APP/IL-1 R1-/-; (C) 9-month-old APP/IL-1 R1+/- and (D) 15-month-old APP/IL-1 R1+/-; (E) 9-month-old wild type Tg2576 
mice (IL-1 R1+/+) and (F) 15-month-old wild type Tg2576 mice (IL-1 R1+/+). (A, B, C, D, E, F magnification = 400×).Journal of Neuroinflammation 2006, 3:17 http://www.jneuroinflammation.com/content/3/1/17
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R1-/- phenotype or some mouse background effect. We
then examined the effects of IL-1 R1 knockout on the state
of microglial activation and astrogliosis surrounding amy-
loid plaques deposits. For microglial staining, we used
two well characterized markers for microglial activation,
anti-mouse CD45 and Iba1, and for activated astrocytes
we used anti-GFAP staining. Our results show that there
were abundant numbers of CD45 and Iba1 immuno-reac-
tive microglia present, surrounding Aβ plaques in APP/IL-
1 R1-/-, APP/IL-1 R1+/- and wild type Tg2576 mice (IL-1
R1+/+), with no significant differences in the immuno-
reactivity of staining using these markers. Similarly,
robust GFAP staining was seen in all three groups of mice
analyzed, with no significant differences seen in the GFAP
immuno-reactivity comparing all three groups of mice.
Based on our immuno-staining analysis, we were not able
to ascertain whether abrogated IL-1 signaling in the IL-1
R1-/- mice blunted the inflammatory microglial response
or astrogliosis in the region of deposited Aβ plaques. Pre-
vious experiments in IL-1 R1-/- mice have shown abro-
gated IL-1-mediated responses following acute
inflammatory stimuli. In a stab wound model of injury in
the brain, IL1-R1-/- mice had fewer amoeboid microglia/
macrophages near the sites of injury, mildly abrogated
astrogliosis and reduced expression of cytokines induced
by IL-1 expression [42]. In another report, IL-1 R1-/- mice
had reduced IL-6 and E-selectin expression, and reduced
IL-1-induced fever and acute phase responses to turpen-
tine [41]. However, IL-1 R1-/- mice do not differ from
control mice in their responses to either a lethal challenge
with D-galactosamine plus LPS or high dose LPS [40],
indicating that IL-1 R1 signaling functions may not be
necessary for the response to LPS. Thus, it is possible that
the chronic nature of the microglial response during the
course of amyloid deposition may abrogate any acute or
subtle signaling events mediated through the IL-1 R1
receptor. Certainly, it is possible that other receptors for
IL-1 may compensate for the lack for IL-1 R1 in this situa-
tion. Besides the IL-1 R1 and IL-1 RII receptors, the
recently reported P2X7 receptor has also been implicated
to be a key player in IL-1 signaling [53] and could com-
pensate for the lack of IL-1R1 in IL-1 mediated signaling
events. Alternatively, the microglial response to deposited
Aβ may not require signaling through the IL-1 R1 recep-
tor. The LPS receptor (CD14) [54,55], the scavenger recep-
tor complex (CD36) [56] and toll-like receptors (TLR-2,
TLR-4) [57] can directly activate microglia in response to
amyloid deposition, possibly circumventing any IL-1 R1-
mediated signaling events in the IL-1 R1-/- mice.
Like our previous studies, these studies suggest that micro-
glial activation is not required for immunization to work
in Tg2576 mice, although this should not be viewed as
definitive. As indicated above, in the IL-1 R1-/- mice,
microgliosis and astrogliosis are mildly abrogated at best
and do not result in microglial paralysis. Thus experi-
ments using recently developed CD11b-HSVTK mice.
developed by Aguzzi and colleagues [58]. that enable
selective killing of microglia cells may provide more
definitive results.
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